Becton, Dickinson and Company (NYSE:BDX) insider Stephen Sichak sold 11,787 shares of Becton, Dickinson and stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $200.46, for a total value of $2,362,822.02. Following the completion of the sale, the insider now owns 14,038 shares of the company’s stock, valued at $2,814,057.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at 202.20 on Wednesday. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The stock has a market cap of $46.01 billion, a price-to-earnings ratio of 58.56 and a beta of 1.06. The stock’s 50 day moving average price is $200.08 and its 200-day moving average price is $191.02.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. The firm had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.35 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be paid a dividend of $0.73 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.44%. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

COPYRIGHT VIOLATION NOTICE: “Stephen Sichak Sells 11,787 Shares of Becton, Dickinson and Company (BDX) Stock” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/13/stephen-sichak-sells-11787-shares-of-becton-dickinson-and-company-bdx-stock.html.

Several analysts recently weighed in on the company. Bank of America Corporation restated a “buy” rating and issued a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Piper Jaffray Companies restated a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday. BidaskClub upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a report on Monday, July 17th. Finally, Cowen and Company restated a “buy” rating and issued a $230.00 price objective on shares of Becton, Dickinson and in a report on Monday, August 14th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. Becton, Dickinson and presently has an average rating of “Buy” and a consensus price target of $196.93.

A number of large investors have recently added to or reduced their stakes in BDX. BlackRock Inc. grew its stake in Becton, Dickinson and by 2,427.8% during the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares during the last quarter. Koch Industries Inc. grew its stake in Becton, Dickinson and by 45,268.7% during the 2nd quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock worth $1,391,000 after buying an additional 1,395,182 shares during the last quarter. Vanguard Group Inc. grew its stake in Becton, Dickinson and by 8.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after buying an additional 1,353,780 shares during the last quarter. Winslow Capital Management LLC purchased a new position in Becton, Dickinson and during the 2nd quarter worth approximately $225,164,000. Finally, Janus Henderson Group PLC grew its stake in Becton, Dickinson and by 1,265.9% during the 2nd quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock worth $236,245,000 after buying an additional 1,122,191 shares during the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Insider Buying and Selling by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.